InvestorsHub Logo
Followers 43
Posts 14806
Boards Moderated 0
Alias Born 09/16/2012

Re: None

Wednesday, 09/15/2021 8:03:16 AM

Wednesday, September 15, 2021 8:03:16 AM

Post# of 689475
Posted this over there but seems to be ignored here:


>>The reasons leading to this survival benefit in this heterogeneous patient group have not been fully identified so far. These patients are now the focus of EORTC 1419, also known as ETERNITY, a large international comprehensive study, assessing potential clinical and biological factors of this long-term survival that may contribute to improved survival in glioblastoma patients in general

https://www.eortc.org/blog/2021/03/23/surviving-glioblastoma-eortc-brain-tumour-group-explores-the-factors-that-contribute-to-long-term-survival/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News